A triple drug approach that blocks the KRAS pathway at three points eliminated pancreatic tumors and prevented resistance in ...

The likelihood of EGFR-positive lung cancer returning is largely tied to how advanced it is when first diagnosed, with lower chances in early stages and higher odds in later stages. Newer targeted ...

Retevmo improved event-free survival in stage 2 to 3A RET fusion-positive non-small cell lung cancer after curative therapy, per phase 3 data. Retevmo (selpercatinib) significantly improved event-free ...

HIGHLIGHTSAmplia’s lead drug narmafotinib enhances the activity of kRAS inhibitors in multiple preclinical cancer models presented at US ...

Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 ...

In welcome good news, Telix says the first stage of its pivotal prostate cancer therapeutic trial has hit its desired safety ...

The global oncology market is projected to nearly triple from $279.98 billion in 2026 to an estimated $748.17 billion by 2035 ...

Equity-Insider.com News Commentary -- The five-year cancer survival rate in the United States has reached a record 70%, reflecting decades of progress in early detection, targeted therapy, and ...

TD Cowen 46th Annual Health Care Conference March 3, 2026 1:50 PM ESTCompany ParticipantsCaroline Litchfield - Executive ...

Enrollment remains on track in Phase 2 pivotal portion of PYNNACLE trial evaluating rezatapopt as monotherapy in platinum-resistant/refractory ...

Selpercatinib demonstrated a highly statistically significant and clinically meaningful improvement in reducing the risk of disease recurrence or death Results from the LIBRETTO-432 trial build on ...

Enrollment remains on track in Phase 2 pivotal portion of PYNNACLE trial evaluating rezatapopt as monotherapy in platinum-resistant/refractory ovarian cancer patients with a TP53 Y220C mutationRezatap ...